Movement Alert｜Hansoh Pharmaceutical Rises 3.17% in Regular Trading, Multiple Catalysts Including Avere-NextCure Merger and HS-20093 Phase III Success Drive Momentum

Market Focus07-16

On July 16, Hansoh Pharmaceutical rose 3.17% in regular trading, trading at 33.28 HKD/share, with turnover of approximately 7.86 million HKD.

On the news front, multiple positive catalysts have been released in quick succession. On July 14, the company announced that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure, Inc. pursuant to a merger agreement. Concurrently, the group granted Avere a global exclusive license for cyclic peptide IL-23 receptor antagonist HS-20118 and participated in a directed offering by Avere, advancing internationalization efforts.

Additionally, on July 10, Hansoh announced that its self-developed B7-H3 targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy, representing the first global Phase III trial confirming significant OS benefit from a B7-H3 ADC in this indication. The company plans to pursue NDA filing in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101455281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101455281","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Rises 3.17% in Regular Trading, Multiple Catalysts Including Avere-NextCure Merger and HS-20093 Phase III Success Drive Momentum","media":"Market Focus","content":"<p><p>On July 16, Hansoh Pharmaceutical rose 3.17% in regular trading, trading at 33.28 HKD/share, with turnover of approximately 7.86 million HKD.</p><p>On the news front, multiple positive catalysts have been released in quick succession. On July 14, the company announced that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure, Inc. pursuant to a merger agreement. Concurrently, the group granted Avere a global exclusive license for cyclic peptide IL-23 receptor antagonist HS-20118 and participated in a directed offering by Avere, advancing internationalization efforts.</p><p>Additionally, on July 10, Hansoh announced that its self-developed B7-H3 targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy, representing the first global Phase III trial confirming significant OS benefit from a B7-H3 ADC in this indication. The company plans to pursue NDA filing in China.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Rises 3.17% in Regular Trading, Multiple Catalysts Including Avere-NextCure Merger and HS-20093 Phase III Success Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Rises 3.17% in Regular Trading, Multiple Catalysts Including Avere-NextCure Merger and HS-20093 Phase III Success Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, Hansoh Pharmaceutical rose 3.17% in regular trading, trading at 33.28 HKD/share, with turnover of approximately 7.86 million HKD.</p><p>On the news front, multiple positive catalysts have been released in quick succession. On July 14, the company announced that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure, Inc. pursuant to a merger agreement. Concurrently, the group granted Avere a global exclusive license for cyclic peptide IL-23 receptor antagonist HS-20118 and participated in a directed offering by Avere, advancing internationalization efforts.</p><p>Additionally, on July 10, Hansoh announced that its self-developed B7-H3 targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy, representing the first global Phase III trial confirming significant OS benefit from a B7-H3 ADC in this indication. The company plans to pursue NDA filing in China.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1101455281","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101455281","pubTimestamp":1784165487,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, Hansoh Pharmaceutical rose 3.17% in regular trading, trading at 33.28 HKD/share, with turnover of approximately 7.86 million HKD.On the news front, multiple positive catalysts have been...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势提醒|豪森制药常规交易上涨3.17%，Avere-NextCure合并和HS-20093 III期成功等多重催化剂推动势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 16, Hansoh Pharmaceutical rose 3.17% in regular trading, trading at 33.28 HKD/share, with turnover of approximately 7.86 million HKD.On the news front, multiple positive catalysts have been released in quick succession. On July 14, the company announced that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure, Inc. pursuant to a merger agreement. Concurrently, the group granted Avere a global exclusive license for cyclic peptide IL-23 receptor antagonist HS-20118 and participated in a directed offering by Avere, advancing internationalization efforts.Additionally, on July 10, Hansoh announced that its self-developed B7-H3 targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy, representing the first global Phase III trial confirming significant OS benefit from a B7-H3 ADC in this indication. The company plans to pursue NDA filing in China.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101455281","isCrawlerRequest":true}